Potential Use of Biological Proteins for Liver Failure Therapy

Pharmaceutics

Kazuaki Taguchi¹  Keishi Yamasaki¹  Hakaru Seo¹  Masaki Otagiri¹ 

[1] Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 862-0082, Japan; E-Mails:

关键词: albumin;    lactoferrin;    erythropoietin;    α₁-acid glycoprotein;    gelatin;    hemoglobin;    nanomedicine;    drug delivery;   

DOI  :  10.3390/pharmaceutics7030255

来源: mdpi

【 摘 要 】

Biological proteins have unlimited potential for use as pharmaceutical products due to their various biological activities, which include non-toxicity, biocompatibility, and biodegradability. Recent scientific advances allow for the development of novel innovative protein-based products that draw on the quality of their innate biological activities. Some of them hold promising potential for novel therapeutic agents/devices for addressing hepatic diseases such as hepatitis, fibrosis, and hepatocarcinomas. This review attempts to provide an overview of the development of protein-based products that take advantage of their biological activity for medication, and discusses possibilities for the therapeutic potential of protein-based products produced through different approaches to specifically target the liver (or hepatic cells: hepatocytes, hepatic stellate cells, liver sinusoidal endothelial cells, and Kupffer cells) in the treatment of hepatic diseases.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.